1.1. Objective 

1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions

1.3. Research Methodology
1.3.1. Supply Side (Revenue Analysis)
1.3.2. Demand Side (Spending Analysis)
1.3.3. Data Heads Tracked
1.3.3.1. Quantitative Research
1.3.3.2. Qualitative Research
1.3.4. List of Primary & Secondary Sources
1.3.4.1. Sample Size
1.3.4.2. Sample Distribution
1.3.5. Market Size Estimation
1.3.5.1. Assumption for the Study
1.3.5.2. Data Triangulation

Executive Summary: Global Cancer Pain Diagnostics Market

3.1. Cancer Market Growth Forecast (US$ Mn), 2017 - 2030

3.2. PEST (Political, Economic, Social, Technological) Analysis

4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturers
4.1.3. Distributor
4.1.4. End Users

4.2. Porter's Five Forces Analysis
4.2.1. Bargaining Power of Suppliers
4.2.2. Bargaining Power of Buyers
4.2.3. Threat of Substitutes
4.2.4. Threat of New Entrants
4.2.5. Degree of Competition

4.3. Market Dynamics 
4.3.1. Key Trends
4.3.2. Growth Drivers
4.3.3. Challenges/ Restraints

4.4. Market Opportunity Assessment
4.4.1. Activity Mapping of Top Players (Ansoff's Matrix)

4.5. Market Growth and Outlook
4.5.1. Market Growth Forecast (US$ Mn), 2017-2030
4.5.1.1. ASTUTE Analysis
4.5.1.2. Optimistic Outlook
4.5.1.3. Reserved Outlook

4.6. Covid-19 Impact Assessment on Market Growth Trend
4.6.1. Growth Trend Shift Analysis
4.6.2. Industry Best Practices

4.7. Epidemiology and Patient Population
4.7.1. Key Findings
4.7.2. Epidemiology and Market Methodology
4.7.3. 8MM Incident Patient Population of Cancer Pain

4.8. Country Wise-Epidemiology of Cancer Pain
4.8.1. United States Epidemiology
4.8.1.1. Assumptions and Rationale
4.8.1.2. Total Incident Cases of Cancer Pain in the United States
4.8.1.3. Age-Specific Incidence of Cancer Pain in United States
4.8.2. EU5 Epidemiology
4.8.2.1. Germany
4.8.2.1.1. Assumptions and Rationale
4.8.2.1.2. Total Incident Cases of Cancer Pain in the Germany
4.8.2.1.3. Age-Specific Incidence of Cancer Pain in Germany
4.8.2.2. France
4.8.2.2.1. Assumptions and Rationale
4.8.2.2.2. Total Incident Cases of Cancer Pain in the France
4.8.2.2.3. Age-Specific Incidence of Cancer Pain in France 
4.8.2.3. Italy
4.8.2.3.1. Assumptions and Rationale
4.8.2.3.2. Total Incident Cases of Cancer Pain in the Italy
4.8.2.3.3. Age-Specific Incidence of Cancer Pain in Italy
4.8.2.4. Spain
4.8.2.4.1. Assumptions and Rationale
4.8.2.4.2. Total Incident Cases of Cancer Pain in the Spain
4.8.2.4.3. Age-Specific Incidence of Cancer Pain in Spain
4.8.2.5. UK
4.8.2.5.1. Assumptions and Rationale
4.8.2.5.2. Total Incident Cases of Cancer Pain in UK
4.8.2.5.3. Age-Specific Incidence of Cancer Pain in UK
4.8.3. Japan Epidemiology
4.8.3.1. Assumptions and Rationale
4.8.3.2. Total Incident Cases of Cancer Pain in Japan
4.8.3.3. Age-Specific Incidence of Cancer Pain in Japan
4.8.4. China Epidemiology
4.8.4.1. Assumptions and Rationale
4.8.4.2. Total Incident Cases of Cancer Pain in China
4.8.4.3. Age-Specific Incidence of Cancer Pain in China
4.8.5. India Epidemiology
4.8.5.1. Assumptions and Rationale
4.8.5.2. Total Incident Cases of Cancer Pain in India
4.8.5.3. Age-Specific Incidence of Cancer Pain in India
4.8.6. Treatment and Management of Cancer Pain
4.8.6.1. Treatment Guidelines
4.8.6.2. WHO guidelines for Cancer Pain Management
4.8.6.3. ESMO guidelines for Cancer Pain Management
4.8.7. Unmet Needs
4.8.8. Marketed Drugs
4.8.8.1. ULTRAM (tramadol hydrochloride): Janssen Ortho, LLC
4.8.8.1.1. Product Description
4.8.8.1.2. Regulatory Milestones
4.8.8.1.3. Clinical Development
4.8.8.1.4. Ongoing Current Pipeline Activity
4.8.8.1.5. Safety and efficacy
4.8.8.1.6. Product Profile
4.8.9. Emerging Drugs
4.8.9.1. Morphine Sulfate: Tetra Bio-Pharma/Cognitive Research Corporation
4.8.9.1.1. Product Description
4.8.9.1.2. Other Development Activities
4.8.9.1.3. Clinical Development
4.8.9.1.4. Clinical Trials Information
4.8.9.1.5. Safety and Efficacy
4.8.9.1.6. Product Profile

5.1. Market Concentration Rate

5.2. Company Market Share Analysis (Value %), 2021

5.3. Competitor Benchmarking

6.1. Key Insights

6.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
6.2.1. Opioids/Narcotics
6.2.1.1. Morphine
6.2.1.2. Fentanyl
6.2.1.3. Others
6.2.2. Non-Opioids
6.2.2.1. Acetaminophen
6.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
6.2.3. Nerve Blocks

7.1. Key Insights

7.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
7.2.1. Lung Cancer
7.2.2. Colorectal Cancer
7.2.3. Breast Cancer
7.2.4. Prostate Cancer
7.2.5. Blood Cancer
7.2.6. Others

8.1. Key Insights

8.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
8.2.1. North America
8.2.1.1. The U.S.
8.2.1.2. Canada
8.2.1.3. Mexico
8.2.2. Europe
8.2.2.1. The UK
8.2.2.2. Germany
8.2.2.3. France
8.2.2.4. Italy
8.2.2.5. Spain
8.2.2.6. Poland 
8.2.2.7. Russia
8.2.2.8. Rest of Europe
8.2.3. Asia Pacific
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia & New Zealand
8.2.3.5. ASEAN
8.2.3.6. Rest of Asia Pacific
8.2.4. Middle East & Africa
8.2.4.1. UAE
8.2.4.2. Saudi Arabia
8.2.4.3. South Africa
8.2.4.4. Rest of MEA
8.2.5. South America
8.2.5.1. Argentina
8.2.5.2. Brazil
8.2.5.3. Rest of South America

9.1. Key Insights

9.2. Regional Market Dynamics and Impact Assessment

9.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
9.3.1. By Drug Type
9.3.2. By Disease Indication
9.3.3. By Country

10.1. Key Insights

10.2. Regional Market Dynamics and Impact Assessment

10.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
10.3.1. By Drug Type
10.3.2. By Disease Indication
10.3.3. By Country

11.1. Key Insights

11.2. Regional Market Dynamics and Impact Assessment

11.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
11.3.1. By Drug Type
11.3.2. By Disease Indication
11.3.3. By Country

12.1. Key Insights

12.2. Regional Market Dynamics and Impact Assessment

12.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
12.3.1. By Drug Type
12.3.2. By Disease Indication
12.3.3. By Country

13.1. Key Insights

13.2. Regional Market Dynamics and Impact Assessment

13.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
13.3.1. By Drug Type
13.3.2. By Disease Indication
13.3.3. By Country

14.1. Key Insights

14.2. Regional Market Dynamics and Impact Assessment

14.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
14.3.1. By Drug Type
14.3.2. By Disease Indication

15.1. Key Insights

15.2. Regional Market Dynamics and Impact Assessment

15.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
15.3.1. By Drug Type
15.3.2. By Disease Indication

16.1. Key Insights

16.2. Regional Market Dynamics and Impact Assessment

16.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
16.3.1. By Drug Type
16.3.2. By Disease Indication

17.1. Key Insights

17.2. Regional Market Dynamics and Impact Assessment

17.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
17.3.1. By Drug Type
17.3.2. By Disease Indication

18.1. Key Insights

18.2. Regional Market Dynamics and Impact Assessment

18.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
18.3.1. By Drug Type
18.3.2. By Disease Indication

19.1. Key Insights

19.2. Regional Market Dynamics and Impact Assessment

19.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
19.3.1. By Drug Type
19.3.2. By Disease Indication

20.1. Key Insights

20.2. Regional Market Dynamics and Impact Assessment

20.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
20.3.1. By Drug Type
20.3.2. By Disease Indication

21.1. Key Insights

21.2. Regional Market Dynamics and Impact Assessment

21.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
21.3.1. By Drug Type
21.3.2. By Disease Indication

22.1. Key Insights

22.2. Regional Market Dynamics and Impact Assessment

22.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
22.3.1. By Drug Type
22.3.2. By Disease Indication

23.1. Aoxing Pharmaceutical Company, Inc.
23.2. BioDelivery Sciences International, Inc.
23.3. CK Life Sciences (WEX Pharmaceuticals)
23.4. Daiichi Sankyo Co., Ltd.
23.5. Hisamitsu Pharmaceutical Co., Inc.
23.6. Mundipharma International Limited
23.7. Orexo AB
23.8. Pfizer Inc.
23.9. Teva Pharmaceutical Industries Limited
23.10. Roche Holding AG
23.11. Other Prominent Players